Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norman R Relkin

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Neurology|August 14, 2024
Is Normal Pressure Hydrocephalus a Complex Genetic Disorder?Norman R Relkin
Expert Review of Neurotherapeutics|June 15, 2007
Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's diseaseNorman R Relkin
The Lancet. Neurology|August 2, 2008
Testing the mettle of PBT2 for Alzheimer's diseaseNorman R Relkin
CNS Spectrums|November 5, 2008
Current state of immunotherapy for Alzheimer's diseaseNorman R Relkin
Neurology. Clinical Practice|November 1, 2013
Diagnosis and management of idiopathic normal-pressure hydrocephalusMichael A Williams, Norman R Relkin
Current Opinion in Molecular Therapeutics|December 24, 2005
Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approachMark D'Ascenzo, Norman R Relkin, Kelvin H Lee
American Journal of Alzheimer'S Disease and Other Dementias|September 5, 2006
Development and testing of a new outcome measure of relationship between patients with Alzheimer's disease and their partnersMargaret C Reilly, Norman R Relkin, Arthur S Zbrozek
Electrophoresis|July 19, 2012
Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapyGilda Shayan, Basia Adamiak, Norman R Relkin, et al.
Immunological Reviews|May 11, 2005
The immune system, amyloid-beta peptide, and Alzheimer's diseaseMarc E Weksler, Gunnar Gouras, Norman R Relkin, et al.
Clinical Neurology and Neurosurgery|September 2, 2009
Upper extremity motor measures of Tap Test response in Normal Pressure HydrocephalusDiamanto Tsakanikas, Heather Katzen, Lisa D Ravdin, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Neurology|August 14, 2024
Is Normal Pressure Hydrocephalus a Complex Genetic Disorder?Norman R Relkin
Expert Review of Neurotherapeutics|June 15, 2007
Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's diseaseNorman R Relkin
The Lancet. Neurology|August 2, 2008
Testing the mettle of PBT2 for Alzheimer's diseaseNorman R Relkin
CNS Spectrums|November 5, 2008
Current state of immunotherapy for Alzheimer's diseaseNorman R Relkin
Neurology. Clinical Practice|November 1, 2013
Diagnosis and management of idiopathic normal-pressure hydrocephalusMichael A Williams, Norman R Relkin
Current Opinion in Molecular Therapeutics|December 24, 2005
Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approachMark D'Ascenzo, Norman R Relkin, Kelvin H Lee
American Journal of Alzheimer'S Disease and Other Dementias|September 5, 2006
Development and testing of a new outcome measure of relationship between patients with Alzheimer's disease and their partnersMargaret C Reilly, Norman R Relkin, Arthur S Zbrozek
Electrophoresis|July 19, 2012
Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapyGilda Shayan, Basia Adamiak, Norman R Relkin, et al.
Immunological Reviews|May 11, 2005
The immune system, amyloid-beta peptide, and Alzheimer's diseaseMarc E Weksler, Gunnar Gouras, Norman R Relkin, et al.
Clinical Neurology and Neurosurgery|September 2, 2009
Upper extremity motor measures of Tap Test response in Normal Pressure HydrocephalusDiamanto Tsakanikas, Heather Katzen, Lisa D Ravdin, et al.
Pageof 4